June 29, 2015 4:38pm
This transaction strengthens Celgene’s position in the emerging and transformative area of immuno-oncology. CELG has leading small molecule and protein capabilities that complement Juno’s advanced engineered T cell capabilities.
JUNO closed DOWN -$0.31 and is UP is UP +43.63% or $20.20 to $66.50 in the aftermarket
Members only. Please login.